Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
Phase III BMT CTN 1703 trial of cyclophosphamide, tacrolimus, and mycophenolate mofetil for prevention of GVHD following alloSCT, presented at ASH 2022 and reported by Clinical Care Options (CCO)
GVHD experts address key questions about the treatment of patients with graft versus host disease in this commentary from Clinical Care Options (CCO)
Expert-selected summary slides on graft-versus-host disease to help diagnose and manage your patients with GVHD, from Clinical Care Options (CCO).
On-demand Clinical Care Options (CCO) webcast: expert faculty discuss treatment options for B-cell lymphomas, including updates from ASH 2021